Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Short Interest Up 116.5% in January

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 130,715 shares, a growth of 116.5% from the December 31st total of 60,376 shares. Based on an average daily volume of 149,034 shares, the short-interest ratio is presently 0.9 days. Approximately 0.8% of the shares of the stock are sold short. Approximately 0.8% of the shares of the stock are sold short. Based on an average daily volume of 149,034 shares, the short-interest ratio is presently 0.9 days.

Institutional Investors Weigh In On Brainsway

Large investors have recently made changes to their positions in the business. ARK Investment Management LLC increased its holdings in Brainsway by 6.1% in the 2nd quarter. ARK Investment Management LLC now owns 199,826 shares of the company’s stock valued at $2,628,000 after purchasing an additional 11,498 shares in the last quarter. Huntleigh Advisors Inc. boosted its position in shares of Brainsway by 5.7% in the second quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock worth $1,018,000 after buying an additional 4,143 shares during the period. Eagle Global Advisors LLC raised its holdings in shares of Brainsway by 9.4% during the 4th quarter. Eagle Global Advisors LLC now owns 81,303 shares of the company’s stock valued at $1,546,000 after buying an additional 6,977 shares during the period. Palumbo Wealth Management LLC boosted its holdings in Brainsway by 37.9% in the 4th quarter. Palumbo Wealth Management LLC now owns 16,320 shares of the company’s stock worth $310,000 after acquiring an additional 4,483 shares during the period. Finally, Y.D. More Investments Ltd grew its position in Brainsway by 559.8% in the fourth quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock valued at $2,187,000 after acquiring an additional 97,537 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BWAY. HC Wainwright lifted their price objective on Brainsway from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Wall Street Zen cut Brainsway from a “buy” rating to a “hold” rating in a report on Friday, January 23rd. Northland Securities set a $30.00 price objective on Brainsway in a research note on Thursday, January 22nd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Brainsway Stock Down 2.8%

Shares of BWAY traded down $0.67 during mid-day trading on Friday, hitting $23.38. The company had a trading volume of 77,950 shares, compared to its average volume of 126,863. Brainsway has a 1-year low of $7.84 and a 1-year high of $25.65. The business’s 50-day simple moving average is $19.84 and its 200-day simple moving average is $16.50. The stock has a market cap of $457.78 million, a PE ratio of 77.93 and a beta of 1.19.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings results on Tuesday, November 11th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03). The company had revenue of $13.51 million for the quarter, compared to analysts’ expectations of $13.04 million. Brainsway had a return on equity of 9.46% and a net margin of 12.73%. On average, sell-side analysts expect that Brainsway will post 0.08 earnings per share for the current year.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.